利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.05 秒)

    METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES
    7.
    发明申请
    METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES 审中-公开
    用于控制抗体血液动力学的方法

    公开(公告)号：US20090324589A1

    公开(公告)日：2009-12-31

    申请号：US12295039

    申请日：2007-03-30

    申请人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    IPC分类号： A61K39/395 ,  C12P21/02 ,  C07K16/18 ,  C12N15/11 ,  C12N5/06

    CPC分类号： C07K16/40 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56

    摘要： The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life in blood had been controlled by the methods of the present invention were confirmed to actually retain the original activity. The methods of the present invention are widely applicable to polypeptides comprising an FcRn-binding domain, such as IgG antibodies, which are recycled via the FcRn salvage pathway regardless of the type of target antigen.

    摘要翻译： 本发明人发现，作为包含FcRn结合结构域的多肽的IgG抗体的血液中的半衰期可以通过在IgG的可变区的残基中修饰暴露于表面的残基来控制表面电荷来控制 抗体。 通过本发明的方法控制血液半衰期的抗体被证实实际上保留了原来的活性。 本发明的方法可广泛应用于包含FcRn结合结构域（例如IgG抗体）的多肽，其通过FcRn补救途径循环，而不管靶抗原的类型如何。

    Methods for controlling blood pharmacokinetics of antibodies
    8.
    发明授权
    Methods for controlling blood pharmacokinetics of antibodies 有权

    公开(公告)号：US11046784B2

    公开(公告)日：2021-06-29

    申请号：US12295039

    申请日：2007-03-30

    申请人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana

    IPC分类号： C07H21/04 ,  C07K16/40

    摘要： The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life in blood had been controlled by the methods of the present invention were confirmed to actually retain the original activity. The methods of the present invention are widely applicable to polypeptides comprising an FcRn-binding domain, such as IgG antibodies, which are recycled via the FcRn salvage pathway regardless of the type of target antigen.

    Method of modifying isoelectric point of antibody via amino acid substitution in CDR
    9.
    发明授权
    Method of modifying isoelectric point of antibody via amino acid substitution in CDR 有权
    通过CDR中氨基酸取代修饰抗体等电点的方法

    公开(公告)号：US09096651B2

    公开(公告)日：2015-08-04

    申请号：US12679922

    申请日：2008-09-26

    申请人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Taichi Kuramochi

    发明人： Tomoyuki Igawa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Taichi Kuramochi

    IPC分类号： A61K39/395 ,  C07K16/00

    CPC分类号： C07K16/2866 ,  A61K39/39591 ,  C07K16/00 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  G01N33/6854

    摘要： Methods are described for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The disclosure also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies with a modified isoelectric point. The disclosure further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.

    摘要翻译： 描述了用于修饰抗体的等电点同时保留其抗原结合活性的方法，包括修饰互补决定区（CDR）表面上至少一个可暴露氨基酸残基的电荷。 本公开还提供了用于纯化多特异性抗体的方法，包括修饰等电点，以及用于改进具有修饰的等电点的抗体的血浆药代动力学的方法。 本公开进一步提供具有修饰的等电点的抗体，包含抗体作为活性成分的药物组合物，以及用于产生抗体和组合物的方法。

    Anti-glypican-3 antibody having improved kinetics in plasma
    10.
    发明授权
    Anti-glypican-3 antibody having improved kinetics in plasma 有权
    具有改善血浆动力学的抗磷脂酰肌醇蛋白聚糖-3抗体

    公开(公告)号：US08497355B2

    公开(公告)日：2013-07-30

    申请号：US12733933

    申请日：2008-09-26

    申请人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    发明人： Tomoyuki Igawa ,  Taichi Kuramochi ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Tatsuhiko Tachibana ,  Takahiro Ishiguro

    IPC分类号： C07K16/30 ,  A61K39/395 ,  C07H21/04 ,  C12P21/08 ,  C12N15/13

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/8258

    摘要： A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.

    摘要翻译： 调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法，一种药物组合物，其包含具有调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，制备抗磷脂酰肌醇蛋白聚糖的方法 提供了包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。 公开了通过改变暴露于抗磷脂酰肌醇蛋白聚糖3抗体表面的氨基酸残基来调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法; 和具有通过氨基酸残基修饰调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体，包含作为活性成分的磷脂酰肌醇蛋白聚糖3抗体的药物组合物，以及制备抗磷脂酰肌醇蛋白聚糖3抗体的方法和 制备包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。